Zola-Cel CAR T-Cell Therapy Shows Promising Initial Results in Multiple Sclerosis

Early results from the Breakfree-2 phase 1 trial indicate that zola-cel, a CD19-directed CAR T-cell therapy, shows promising safety and efficacy in treating highly active relapsing and progressive multiple sclerosis, with sustained clinical stability and disease improvement at six months post-infusion.

This Wire brief sits within Fusion42's coverage of Biotech.